MIP Search | Managing Intellectual Property

Is China’s utility model system getting a bad rap?

A recent report published by IP Key suggests that China’s utility model system contains safeguards to help ensure patent quality not always found in other countries

January 28 2015

Valideus launches in US with Neuman hire

New gTLD specialist Valideus, based in London, is launching a sister company, Valideus USA, based in Virginia, USA

January 26 2015

New lawyer for Gorodissky

Valery Narezhny has joined the IP department of Gorodissky & Partners in Moscow, where he will be in charge of new practices such as tax, Customs and commercial law

January 26 2015

A spotlight on parliamentary lobbying

Pirate Party MEP Julia Reda, who this month published a report on copyright for the European Parliament’s Legal Affairs Committee, wants greater transparency about political lobbying. Is your company on her list?

January 28 2015

How to survive multinational patent litigation

It’s more and more common for complex IP disputes to involve proceedings in multiple jurisdictions. If you’re preparing for patent litigation take-off, please fasten your seat belt and join James Nurton for a safety demonstration

January 29 2015

Argentina: New Civil and Commercial Code

Since industrial property rights in general constitute essential elements in the operation of modern business, their study habitually forms part of the commercial law. Thus, in the Argentine Republic, trade mark and patent laws are complementary to the Commercial Code that is in force.

Managing IP Correspondent, January 26 2015

Australia: Criteria for pharmaceutical term extensions clarified

To compensate patent owners for the time it takes to obtain regulatory and marketing approval for new drugs, the Australian Patents Act provides for patent term extensions of up to five years. However, in order to have an extension of term granted, a number of requirements need to be satisfied. One of these requirements is that a patent discloses and claims a pharmaceutical substance per se or a pharmaceutical substance produced by a process that involves the use of recombinant DNA technology.

Managing IP Correspondent, January 26 2015

Austria: Bad faith and intent to use

According to Austrian law, reasons for trade mark invalidity, such as bad faith, can be raised as defences in an infringement action. Such defences have to be decided as preliminary questions.

Managing IP Correspondent, January 26 2015

Belgium: Prima facie validity of European patents

Interim measures and preliminary injunctions are frequently used in Belgian and European (cross-border) patent litigation conflicts. Belgian courts can generally order such measures upon a prima facie assessment of the validity of the claimant's IP rights, which includes neither a full legal analysis nor a substantial technical examination.

Managing IP Correspondent, January 26 2015

USPTO appoints law professor as Detroit satellite office director

University of Nebraska College of Law professor Christal Sheppard has been appointed as the first director of the USPTO’s satellite office in Detroit

January 26 2015

Search results for